Systemic clearance and demethylation of caffeine in sheep and cattle

Drug Metabolism and Disposition

Volumn 24, Issue 10, 1996, Pages 1058-1061

  Danielson, Terry J ^a   Golsteyn, Lorraine R ^a  

^a LETHBRIDGE RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450; ETOFYLLINE; PARAXANTHINE; THEOBROMINE; THEOPHYLLINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CATTLE; CONTROLLED STUDY; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; INTRAVENOUS DRUG ADMINISTRATION; LIVER CLEARANCE; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; SHEEP; SPECIES DIFFERENCE;

ANIMALS; CAFFEINE; CATTLE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; FEMALE; HALF-LIFE; METHYLATION; REFERENCE STANDARDS; SHEEP;

ANIMALIA; BOS TAURUS; OVIS ARIES;

EID: 0029957551     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. M. Burke, C. Thompson, J. Elcombe, T. Halpert, T. Haaparanta, and R. Mayer: Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem. Pharmacol. 34, 3337-3345 (1985).
2. R. Lubet, R. Mayer, J. Cameron, R. Nims, M. D. Burke, T. Wolff, and F. Guengerich: Dealkylation of pentoxyresorufin: a rapid and sensitive assay for measuring induction of cytochrome(s) P-450 by phenobarbital and other xenobiotics in the rat. Arch. Biochem. Biophys. 238, 43-48 (1985).
3. P. V. Nerurkar, S. S. Park, P. E. Thomas, R. W. Nims, and R. A. Lubet: Methoxyresorufin and benzyloxyresorufin - substrates preferentially metabolized by cytochrome-P4501A2 and cytochrome-2B, respectively, in the rat and mouse. Biochem. Pharmacol. 46, 933-943 (1993).
4. W. Tassaneeyakul, D. J. Birkett, M. E. Verronese, M. E. McManus, R. H. Tukey, L. C. Quattrochi, H. V. Gelboin, and J. D. Miners: Specificity of substrate and inhibitor probes for human cytochromes-P450 1A1 and 1A2. J. Pharmacol Exp. Ther. 265, 401-407 (1993).
5. W. Tassaneeyakul, D. J. Birkett, M. E. McManus, W. Tassaneeyakul, M. E. Veronese, T. Anderson, R. S. Tukey, and J. O. Miners: Caffeine metabolism by human hepatic cytochromes P450 - contributions of 1A2, 2E1, and 3A isoforms. Biochem. Pharmacol. 47, 1767-1776 (1994).
6. G. A. E. van't Klooster, B. J. Blaauboer, J. Noordhoek, and A. S. J-. P. A. M. van Miert: Cytochrome-P450 induction and metabolism of alkoxyresorufins, ethylmorphine and testosterone in cultured hepatocytes from goats, sheep and cattle. Biochem. Pharmacol. 46, 1781-1790 (1993).
7. G. Marchesini, G. A. Checchia, G. Grossi, R. Lolli, G. P. Bianchi, M. Zoli, and E. Pisi: Caffeine intake, fasting caffeine and caffeine clearance in patients with liver diseases. Liver 8, 241-246 (1988).
8. F. Berthou, B. Guillois, C. Riche, Y. Dreano, E. Jacqz-Aigrain, and P. H. Beaune: Interspecies variations in caffeine metabolism related to cytochrome P4501A enzymes. Xenobiotica 19, 671-680 (1992).
9. W. Tassaneeyakul, Z. Mohamed, D. J. Birkett, M. E. McManus, M. E. Veronese, R. S. Tukey, L. C. Quattrochi, F. J. Gonzalez, and J. O. Miners: Caffeine as a probe for human cytochromes P450: validation using cDNA-expression immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 2, 173-183 (1992).
10. M. Bonati, R. Latini, G. Tognoni, J. F. Young, and S. Garattini: Interspecies comparisons of in vivo caffeine pharmacokinetics in man, monkey, rabbit, rat and mouse. Drug Metab. Rev. 15, 1355-1383 (1985).
11. U. Fuhr and K. L. Rost: Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics 4, 109-116 (1994).
12. PA (P-4501A2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc. Natl. Acad. Sci. U.S.A. 86, 7696-7700 (1989).
13. C. Cazeneuve, G. Pons, E. Rey, J. M. Treluyer, T. Cresteil, G. Thiroux, P. Dathis, and G. Olive: Biotransformation of caffeine in human liver microsomes from foetuses, neonates, infants and adults. Br. J. Clin. Pharmacol. 37, 405-412 (1994).
14. J. W. Daly, W. L. Padgett, and M. T. Shamim: Analogues of caffeine and theophylline: effects of structural alterations on affinity at adenosine receptors. J. Med. Chem. 29, 1305-1308 (1986).
15. D. B. Haughey, R. Greenberg, S. F. Schaal, and J. L. Lima: Liquid chromatographic determination of caffeine in biological fluids. J. Chromatogr. 229, 387-395 (1982).
16. K. Yamaoka, T. Nakagawa, and T. Uno: Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6, 165-175 (1978).
17. M. Gibaldi and D. Perrier: "Pharmacokinetics," 2nd ed. Marcel Dekker, New York, 1982.
18. G. A. E. van't Klooster, F. M. A. Woutersenvannijanten, B. J. Blaauboer, J. Noordhoek, and A. S. J. P. A. M. van Miert: Applicability of cultured hepatocytes derived from goat, sheep and cattle in comparative drug metabolism studies. Xenobiotica 24, 417-428 (1994).
19. I. C. Shaw: The use of in vitro methods for studying drug metabolism to replace animal studies as part of veterinary product license applications. Toxicol. In Vitro 8, 917-919 (1994).
20. D. M. Boothe, J. M. Cullen, J. A. Calvin, W. L. Jenkins, S. A. Brown, R. A. Green, and D. E. Corner: Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver diseases. Am. J. Vet. Res. 55, 254-261 (1994).
21. F. L. S. Tse, K. H. Valia, T. W. Szeto, T. J. Raimondo, and B. Koplowitz: Effect of caffeine on circulating theophylline levels in beagle dogs. J. Pharm. Sci. 70, 395-399 (1981).
22. E. W. Greene, W. E. Woods, and T. Tobin: Pharmacology, pharmacokinetics and behavioral effects of caffeine in horses. Am. J. Vet. Res. 44, 57-63 (1983).
23. P. Bullock, R. Pearce, A. Draper, J. Podval, W. Bracken, J. Veltman, P. Thomas, and A. Parkinson: Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug Metab. Dispos. 23, 736-748 (1995).
24. S. Gilbert, B. Stavric, R. Klassen, and D. Rice: The fate of chronically consumed caffeine in the monkey (Macacca fasicularis). Fundam. Appl. Toxicol. 5, 578-587 (1985).
25. L. M. Distlerath, P. E. B. Reilly, M. V. Martin, G. G. Davis, G. R. Wilkinson, and F. P. Guengerich: Purification and characterization of human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation: two prototypes for genetic polymorphism in oxidative drug metabolism. J. Biol. Chem. 260, 9057-9067 (1985).
26. H. K. Kroemer, J. C. Gautire, P. Beaune, C. Henderson, C. R. Wolf, and M. Eichelbaum: Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn-Schmiedebergs Arch. Pharmacol. 348, 332-337 (1993).
27. S. Botach, J. C. Gautier, P. Beaune, M. Eichelbaum, and H. K. Kroemer: Identification and characterization of the cytochrome-P450 enzymes involved in the N-dealkylation of propaphenone - molecular base for the interaction potential and variable disposition of active metabolites. Mol. Pharmacol. 43, 120-126 (1993).
28. L. Bertilsson, J. O. Carrillo, M. L. Dahl, A. Lierena, C. Alm, U. Bondesson, L. Lindstrom, I. R. Delarubia, S. Ramos, and J. Benitez: Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br. J. Clin. Pharmacol. 38, 471-473 (1994).
29. 1 and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12, 255-259 (1991).
30. E. P. Gallagher, L. C. Wienkers, P. L. Stapleton, K. L. Kunze, and D. L. Eaton: Role of human microsomal and human complementary DNA-expressed cytochrome-P4501A2 and cytochrome-P4503A4 in the bioactivation of aflatoxin-B(1). Cancer Res. 54, 101-108 (1994).
31. R. J. Edwards, B. P. Murray, S. Murray, T. Schultz, D. Neubert, T. W. Gant, S. S. Thorgeirsson, A. R. Boobis, and D. S. Davies: Contribution of CYP1A1 and CYP1A2 to the activation of heterocyclic amines in monkeys and man. Carcinogenesis 15, 829-836 (1994).
32. A. R. Boobis, A. M. Lynch, S. Murray, R. Delatorre, A. Solans, M. Farre, J. Segura, N. J. Gooderham, and D. S. Davies: CYP1A2-catalyzed conversion of dietary heterocyclic amines to their proximate carcinogens is their major route of metabolism in humans. Cancer Res. 54, 89-94 (1994).